Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020）

NCT03755869 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

103

Enrollment

OTHER

Sponsor class

Conditions

Non-squamous NSCLC

Interventions

DRUG: Anlotinib

Sponsor

First Affiliated Hospital Xi'an Jiaotong University

Collaborators

[object Object]
[object Object]